Table 1 Baseline characteristics

Mean ± SD

ADA+MTX

(n = 268)

PBO+MTX

(n = 257)

ADA+MTX

(n = 515)

PBO+MTX

(n = 517)

Age, years

51.9 ± 14.0

52.0 ± 13.1

50.7 ± 14.5

50.4 ± 13.6

Female, n (%)

193 (72.0)

190 (73.9)

380 (73.8)

382 (73.9)

Caucasian, n (%)

250 (93.3)

242 (94.2)

460 (89.3)

464 (89.7)

Duration of RA, years

0.7 ± 0.8

0.8 ± 0.9

0.3 ± 0.3

0.4 ± 0.6

CRP, mg/dL

3.9 ± 4.2

4.0 ± 4.0

2.7 ± 3.2

3.0 ± 3.3

DAS28(CRP)

6.3 ± 0.9

6.3 ± 0.9

6.0 ± 1.0

6.0 ± 1.0

CDAI

43.6 ± 12.6

44.4 ± 11.9

41.3 ± 13.2

40.3 ± 13.3

SDAI

47.4 ± 14.2

48.4 ± 13.4

44.0 ± 14.2

43.2 ± 14.6

TJC68

30.7 ± 14.2

32.3 ± 14.3

29.0 ± 15.0

27.2 ± 14.5

SJC66

21.1 ± 11.2

22.1 ± 11.7

18.3 ± 10.5

17.9 ± 10.5

PGA

65.1 ± 17.6

65.6 ± 17.7

63.0 ± 17.8

62.2 ± 18.3

PtGA

66.8 ± 22.1

63.0 ± 25.0

64.0 ± 23.0

62.5 ± 22.1

Pt pain

62.5 ± 21.3

59.6 ± 24.3

65.0 ± 21.3

64.7 ± 21.2

HAQ-DI

1.5 ± 0.6

1.5 ± 0.6

1.6 ± 0.7

1.6 ± 0.7

ADA+MTX

(n = 207)

PBO+MTX

(n = 200)

ADA+MTX

(n = 67)

PBO+MTX

(n = 62)

Age, years

56.1 ± 13.5

56.1 ± 12.0

57.2 ± 11.4

56.0 ± 10.8

Female, n (%)

158 (76.3)

146 (73.0)

50 (74.5)

51 (82.3)

Caucasian, n (%)

173 (83.6)

166 (83.0)

58 (86.6)

45 (72.6)

Duration of RA, years

11.0 ± 9.2

10.9 ± 8.8

12.2 ± 11.1

11.1 ± 8.0

CRP, mg/dL

1.8 ± 2.3

1.8 ± 2.1

2.1 ± 1.8

3.1 ± 3.9

DAS28(CRP)

5.7 ± 0.9

5.8 ± 0.9

5.1 ± 0.7

5.1 ± 1.0

CDAI

38.6 ± 12.2

40.3 ± 12.3

37.3 ± 10.7

37.3 ± 11.7

SDAI

40.6 ± 13.0

42.1 ± 12.9

39.5 ± 10.7

40.4 ± 13.5

TJC68

27.3 ± 12.7

28.1 ± 13.8

28.0 ± 12.7

28.7 ± 15.2

SJC66

19.3 ± 9.8

19.0 ± 9.5

17.3 ± 8.6

16.9 ± 9.5

PGA

62.0 ± 16.7

61.3 ± 17.3

58.7 ± 15.8

58.9 ± 15.3

PtGA

52.7 ± 21.0

54.3 ± 22.9

56.9 ± 21.1

58.0 ± 23.2

Pt pain

55.9 ± 20.4

56.3 ± 22.9

53.0 ± 22.0

57.2 ± 21.0

HAQ-DI

1.5 ± 0.6

1.5 ± 0.6

1.6 ± 0.6

1.6 ± 0.6